WHITE PAPER
Synchro VasQ
RightLight TM Technology
Enhanced Dye Wavelengths
SYNCHRO VASQ
DEKA White Paper
February 2013
RightLight TM Technology
Enhanced Dye Wavelengths
Prof. P. Campolmi, Prof. G.Cannarozzo, Prof. P. Bonan,
Italian Group of Laser Dematology - Dermatological Clinic University of Florence (Italy)
Prof. A. Pacifici - Clinical Laser (Perugia - Italy)
Vascular Lesions of the Face
S
uperficial vascular lesions of the face have been
effectively treated, using light sources with both
visible (500-800 nm) and near infrared (800-1300 nm)
wavelengths. The most widespread systems used to
treat vascular anomalies were KTP (532 nm), copper
vapour laser (511/578 nm), Alexandrite (755 nm), Diode
laser (800/810/930 nm), before current systems, such
as Dye laser, Nd:Yag laser and Pulsed Light systems
were identified.
As of today, Dye laser represents the established
standard for treating superficial vascular lesions. The
Figure 1. Absorption spectrum of the main skin chromophores.
target of vascular lesion treatment is, in fact, the
oxyhemoglobin, which presents three wavelength
absorption peaks: 418, 542 and 577 nm (Fig.1).
After a first analysis, the most effective therapeutic
wavelength must be chosen by identifying the highest
absorption of the vascular chromophore. However,
vascular lesion anatomy implies that wavelength
penetration depth must also be taken into account.
In particular, a higher wavelength allows for deeper
penetration to reach the level of the dermis where the
vascular lesion is located. The current Dye lasers, which
use rhodamine as the active medium, allow producing
wavelengths ranging between 585 and 600 nm.
These wavelengths allow obtaining deeper penetration
into the tissues to treat even lesions morphologically
distributed in-depth, whilst maintaining high
haemoglobin selectivity (Fig.1). The undisputed
therapeutic advantage of these wavelengths, linked
to the haemoglobin absorption selectivity, which
makes Dye laser the gold standard in vascular lesion
treatment, can, however, create some discomfort in
the treatment of aesthetic disorders because of the
possible formation of purple bruises.
Nd:YAG laser is another system of undisputed
therapeutic value, which allow for near-infrared
emissions with a wavelength of 1064 nm. The thermal
effect on the vascular component has a rationale
similar to that of Dye laser, despite not having its
high haemoglobin absorption peaks with the visible
Figure 2. A) Telangiectasias on the face. B) After 2 Tx with RightLight TM handpiece. (Photo under polarised light courtesy of
Prof. P. Campolmi, Prof. G.Cannarozzo, Prof. P. Bonan, Florence, Italy
www.dekalaser.com
1
DEKA White Paper
SYNCHRO VASQ
wavelength, which require a larger amount of energy.
Its deeper penetration allows treating vascular anomalies
through emissions corresponding to the thermal relaxation
time of the vessels, thereby sparing the surrounding
tissue without the formation of purple bruises.
In addition to the laser systems described up until
now, technological innovation has introduced pulsed
light systems, which allow for broadband emissions,
with a spectrum of wavelengths ranging between 500
and 1200 nm.
The advantage of pulsed light systems lies in the
fact that they allow hitting the target of the vascular
component over several wavelengths, exploiting both
the components of the laser systems described up
until now and other wavelengths that fall within their
emission spectrum.
The use of pulse cooling and handling systems has
made pulsed light a valid system to treat superficial
February 2013
vascular lesions, as it allows managing the emission
whilst maintaining the integrity of the adjacent
structures that are not involved in the treatment.
Though featuring lower performance than Dye laser
and Nd:YAG because of its nonspecificity, pulsed light
has allowed reducing the side effects described above
and treating wide tissue areas, thanks to the larger
size of the waveguides compared to the laser system
spot size.
The largest limit of pulsed light in vascular treatment
is linked to its constructive technology, which leads to
higher energy emission in the infrared, leaving a lower
percentage of light energy in the visible emission,
where both the haemoglobin absorption peaks and
typical wavelengths of Dye laser systems are located.
Moreover, the emission over the entire visible spectrum
involves the pigmentary component in the skin tissue,
which covers the entire visible spectrum with greater
selectivity for increasingly shorter wavelengths (Fig.1).
Figure 3. A) Telangiectasias on the face. B) After 2 Tx with RightLight TM handpiece. (Photo under polarised light courtesy of Prof. A.
Pacifici Perugia, Italy)
Figure 4. A) Telangiectasias on the face. B) Immediately after Tx with RightLight TM handpiece. (courtesy of Prof. A. Pacifici, Perugia, Italy)
2
www.dekalaser.com
DEKA White Paper
SYNCHRO VASQ
February 2013
Figure 5. RightLightTM Technology handpiece.
Figure 5. Post-treatment erythema in Split Face: A) Traditional IPL, B)
RightLight TM handpiece. (Courtesy of Prof. A.Pacifici, Perugia, Italy)
RightLight TM Technology
but only interactions over the pigmentary component
and it is usually eliminated in traditional pulsed light
systems by using filters.
T
he RightLight TM technology handpiece, on the
SynchroVasQ platform, is a pulsed light system
that allows enhancing emission performance in the
wavelength range between 550 and 650 nm, in order to
obtain pulsed light performance closer to Dye laser’s,
thereby creating an effective and more comfortable
treatment (Fig.5).
The system uses rhodamine as a fluorescent substance
that can absorb the wavelengths in the UV spectrum
up to 550 nm and emit them again in fluorescence
within a range between 550-650 nm, with a rhodamine
peak around 570 nm, without losing energy during this
transformation (Fig.6).
This system of shifting the emission band via
fluorescence can also allow exploiting the component
closest to ultraviolet (between 450 and 500 nm), not
selected for vascular treatment.
This range of wavelengths between 450 and 500 nm
of the lamp would not produce therapeutic effects
Figure 6. Moving emission frequencies using rhodamine with
100% efficiency.
This system aims at not eliminating an important
amount of energy and, rather, transferring it to a
vascular frequency range, as in the case of Dye laser
Figure 7. A) Telangiectasias on the nose. B) After 1 Tx with RightLight TM handpiece. (Photo under natural [l-h] and polarised light [r-h]
(courtesy of Prof. P. Campolmi, Prof. G. Cannarozzo, Prof. P. Bonan, Florence, Italy)
www.dekalaser.com
3
DEKA White Paper
SYNCHRO VASQ
February 2013
Figure 8. A) Spider nevus. B) After 1 Tx with RightLight TM handpiece. (Photo under polarised light courtesy of Prof. P. Campolmi,
Prof. G.Cannarozzo, Prof. P. Bonan, Florence, Italy)
specifications, to increase both energy efficiency and
its performance on the haemoglobin chromophore
(Fig. 2, 3, 4, 7, 8, 10, 11 e 12).
All this allows obtaining an amount of energy that falls
within the range between 550-650 nm greater than
traditional pulsed light systems, which translates into
higher performance on vascular lesions (Fig.9).
The use of waveguides, which transfers the energy
generated by the lamp and subsequently optimised
on the tissue, allows moving the mechanics of the
lamp away from the skin to increase visibility of the
treatment area (Fig.5).
Moreover, greater visibility and reduced treatment
area allow adapting the handpiece to every area of the
face to effectively reach those that are most difficult to
access, such as the wing of the nose (Fig.7).
Finally, optimised cooling of the waveguide allows
protecting the epidermis against pulsed light radiation,
thereby maintaining the integrity of the surrounding tissues.
Figure 9. Increase in vascular performance.
In addition, cooling is also used to generate a local
anaesthetic effect over the radiated area, making the
treatment more comfortable.
Figure 10. A) Rosacea. B) After 1 Tx with RightLightTM handpiece. (Courtesy of Prof. P. Campolmi, Prof. G. Cannarozzo, Prof. P. Bonan,Florence, Italy)
4
www.dekalaser.com
DEKA White Paper
SYNCHRO VASQ
February 2013
Figure 11. A) Rosacea. B) After 2 Tx with RightLight TM handpiece. (Photo under polarised light courtesy of Prof. A.Pacifici, Perugia, Italy)
Figure 12. A) Telangiectasias on the face. B) After 1 Tx with RightLight TM handpiece. (Photo under polarised light courtesy of
Prof. P. Campolmi, Prof. G. Cannarozzo, Prof. P. Bonan, Florence, Italy)
Conclusion
References
I
J Cosmet Laser Ther. 2007 Jun; 9(2):113-24.
n conclusion, as clinically proven, the RightLight TM
technology handpiece enhances the performance in the
working range of Dye laser systems, thereby allowing
dispensing larger amounts of energy in the wavelengths
for treating vascular lesions with reduced side effects.
www.dekalaser.com
Vascular lasers and IPLS: guidelines for care from the
European Society for LaserDermatology (ESLD).
Adamic M, Troilius A, Adatto M, Drosner M, Dahmane R.
5
© DEKA Rev. 2.0 - All rights reserved
www.dekalaser.com
DEKA M.E.L.A. s.r.l.
Via Baldanzese,17 - 50041 Calenzano (FI) - Italy
Tel. +39 055 8874942 - Fax +39 0558832884
DEKA M.E.L.A. s.r.l. - All rights reserved - In order to improve its products the company reserves the right to modify these specifications without prior notice.